Your browser doesn't support javascript.
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
Fougeroux, Cyrielle; Goksøyr, Louise; Idorn, Manja; Soroka, Vladislav; Myeni, Sebenzile K; Dagil, Robert; Janitzek, Christoph M; Søgaard, Max; Aves, Kara-Lee; Horsted, Emma W; Erdogan, Sayit Mahmut; Gustavsson, Tobias; Dorosz, Jerzy; Clemmensen, Stine; Fredsgaard, Laurits; Thrane, Susan; Vidal-Calvo, Elena E; Khalifé, Paul; Hulen, Thomas M; Choudhary, Swati; Theisen, Michael; Singh, Susheel K; Garcia-Senosiain, Asier; Van Oosten, Linda; Pijlman, Gorben; Hierzberger, Bettina; Domeyer, Tanja; Nalewajek, Blanka W; Strøbæk, Anette; Skrzypczak, Magdalena; Andersson, Laura F; Buus, Søren; Buus, Anette Stryhn; Christensen, Jan Pravsgaard; Dalebout, Tim J; Iversen, Kasper; Harritshøj, Lene H; Mordmüller, Benjamin; Ullum, Henrik; Reinert, Line S; de Jongh, Willem Adriaan; Kikkert, Marjolein; Paludan, Søren R; Theander, Thor G; Nielsen, Morten A; Salanti, Ali; Sander, Adam F.
  • Fougeroux C; AdaptVac Aps, 2970, Hørsholm, Denmark.
  • Goksøyr L; AdaptVac Aps, 2970, Hørsholm, Denmark.
  • Idorn M; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Soroka V; Department of Biomedicine, Aarhus University, 8000, Aarhus, Denmark.
  • Myeni SK; ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark.
  • Dagil R; Department of Medical Microbiology, Leiden University Medical Center, ZA, Leiden, 2333, Netherlands.
  • Janitzek CM; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Søgaard M; VAR2pharmaceuticals, 2200, Copenhagen, Denmark.
  • Aves KL; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Horsted EW; ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark.
  • Erdogan SM; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Gustavsson T; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Dorosz J; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Clemmensen S; Turkish Ministry of Agriculture and Forestry, 06800, Ankara, Turkey.
  • Fredsgaard L; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Thrane S; VAR2pharmaceuticals, 2200, Copenhagen, Denmark.
  • Vidal-Calvo EE; ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark.
  • Khalifé P; ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark.
  • Hulen TM; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Choudhary S; AdaptVac Aps, 2970, Hørsholm, Denmark.
  • Theisen M; VAR2pharmaceuticals, 2200, Copenhagen, Denmark.
  • Singh SK; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Garcia-Senosiain A; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Van Oosten L; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Pijlman G; VAR2pharmaceuticals, 2200, Copenhagen, Denmark.
  • Hierzberger B; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Domeyer T; Department for Congenital Disorders, Statens Serum Institute, 2300, Copenhagen, Denmark.
  • Nalewajek BW; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Strøbæk A; Department for Congenital Disorders, Statens Serum Institute, 2300, Copenhagen, Denmark.
  • Skrzypczak M; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
  • Andersson LF; Department for Congenital Disorders, Statens Serum Institute, 2300, Copenhagen, Denmark.
  • Buus S; Department of Plant Sciences, Laboratory of Virology, 6700AA, Wageningen, Netherlands.
  • Buus AS; Department of Plant Sciences, Laboratory of Virology, 6700AA, Wageningen, Netherlands.
  • Christensen JP; ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark.
  • Dalebout TJ; ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark.
  • Iversen K; ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark.
  • Harritshøj LH; ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark.
  • Mordmüller B; ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark.
  • Ullum H; ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark.
  • Reinert LS; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Danmark.
  • de Jongh WA; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Danmark.
  • Kikkert M; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Danmark.
  • Paludan SR; Department of Medical Microbiology, Leiden University Medical Center, ZA, Leiden, 2333, Netherlands.
  • Theander TG; Department of Cardiology, Herlev Hospital, 2730, Herlev, Denmark.
  • Nielsen MA; Department of Clinical Immunology, Copenhagen University Hospital, 2100, Copenhagen, Denmark.
  • Salanti A; Universitätsklinikum Tübingen, Institut für Tropenmedizin, 72074, Tübingen, Germany.
  • Sander AF; Centre de Recherches Médicales de Lambaréné, BP 242, Lambaréné, Gabon.
Nat Commun ; 12(1): 324, 2021 01 12.
Article in English | MEDLINE | ID: covidwho-1026822
ABSTRACT
The rapid development of a SARS-CoV-2 vaccine is a global priority. Here, we develop two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. RBD antigens are displayed on AP205 CLPs through a split-protein Tag/Catcher, ensuring unidirectional and high-density display of RBD. Both soluble recombinant RBD and RBD displayed on CLPs bind the ACE2 receptor with nanomolar affinity. Mice are vaccinated with soluble RBD or CLP-displayed RBD, formulated in Squalene-Water-Emulsion. The RBD-CLP vaccines induce higher levels of serum anti-spike antibodies than the soluble RBD vaccines. Remarkably, one injection with our lead RBD-CLP vaccine in mice elicits virus neutralization antibody titers comparable to those found in patients that had recovered from COVID-19. Following booster vaccinations, the virus neutralization titers exceed those measured after natural infection, at serum dilutions above 110,000. Thus, the RBD-CLP vaccine is a highly promising candidate for preventing COVID-19.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Protein Binding / Capsid / Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 Type of study: Diagnostic study Topics: Vaccines Limits: Animals / Female / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-020-20251-8

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Protein Binding / Capsid / Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 Type of study: Diagnostic study Topics: Vaccines Limits: Animals / Female / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-020-20251-8